Aerobic exercise training for patients with Type III Spinal Muscular Atrophy
The Effect of Aerobic Exercise Training in Patients With Type III Spinal Muscular Atrophy"
This study is testing whether aerobic exercise can help improve movement, breathing, and overall quality of life for people with Type III Spinal Muscular Atrophy who can walk and are on Nusinersen therapy.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 10 Years to 50 Years |
| Sex | All |
| Sponsor | Istanbul Medipol University Hospital Academic / other |
| Locations | 1 site (Istanbul, Fatih) |
| Trial ID | NCT05544994 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of aerobic exercise training on motor and respiratory functions, exercise capacity, fatigue, and quality of life in patients with Type III Spinal Muscular Atrophy (SMA) who are able to walk and are receiving Nusinersen therapy. It aims to include twenty patients aged 10-50 years with a confirmed genetic diagnosis of SMA. The study will assess how structured aerobic exercise impacts their overall health and well-being. Previous research suggests that exercise may enhance motor neuron survival and improve physical functioning without causing muscle damage.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 10-50 with a genetically confirmed diagnosis of SMA Type III who can walk independently.
Not a fit: Patients who are using other SMA treatments besides Nusinersen or those with serious systemic diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the quality of life and physical capabilities of patients with Type III SMA.
How similar studies have performed: While some previous studies have shown positive effects of exercise in SMA patients, this specific approach combining aerobic training with Nusinersen therapy is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Have been diagnosed of SMA Type 3 confirmed by genetic analysis, * Between the ages of 10-50, * Being able to walk 25 m without assistive device Exclusion criteria: * Using research drugs for SMA treatment other than Nusinersen treatment, * Having a serious systemic disease that may prevent exercise, * Have had a lower extremity injury and/or surgery in the last 6 months, * To be applying a regular aerobic training program in the last 6 months
Where this trial is running
Istanbul, Fatih
- Istanbul Faculty of Medicine, Department of Neurological Sciences — Istanbul, Fatih, Turkey (Recruiting)
Study contacts
- Principal investigator: Sezan Mergen KILIÇ, MSc PT — Istanbul University, Istanbul Faculty of Medicine,Department of Neurological Sciences
- Study coordinator: Sezan Mergen KILIÇ, MSc PT
- Email: sezanmer@hotmail.com
- Phone: 05324569628
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.